Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

0.8378
+0.191729.67%
Post-market: 0.84600.0082+0.98%17:15 EDT
Volume:5.41M
Turnover:4.22M
Market Cap:100.50M
PE:-0.58
High:0.8600
Open:0.7060
Low:0.6700
Close:0.6461
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global

Reuters
·
3 hours ago

Invivyd Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
08 May

What's Going On With Invivyd Stock On Monday?

Benzinga
·
21 Apr

BRIEF-Invivyd Announces $30M Non-Dilutive Loan Facility With Silicon Valley Bank

Reuters
·
21 Apr

Invivyd Announces $30M Non-Dilutive Loan Facility With Silicon Valley Bank

THOMSON REUTERS
·
21 Apr

Press Release: Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Dow Jones
·
21 Apr

Invivyd Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Mar

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

THOMSON REUTERS
·
20 Mar

Invivyd Inc - Vyd2311 Commercial Manufacturing Completed, Minimal Expenses Expected in 2025

THOMSON REUTERS
·
20 Mar

Invivyd Inc: Continues to Target Profitability by End of 1H 2025

THOMSON REUTERS
·
20 Mar

Invivyd Inc - Q4 2024 Pemgarda Revenue $13.8 Mln, up 48% From Q3 2024

THOMSON REUTERS
·
20 Mar

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
05 Mar

Invivyd Inc: Pemivibart Antiviral Activity Remains Within Range of Expected Assay Variability Since Omicron Ba.2

THOMSON REUTERS
·
05 Mar

Invivyd Inc - Vyd2311 Shows Clinically Meaningful Neutralization Against Lp.8.1

THOMSON REUTERS
·
05 Mar

Invivyd Announces Continued Neutralizing Activity of Pemgarda™ (Pemivibart) Against Currently Dominant Sars-Cov-2 Variant Lp.8.1

THOMSON REUTERS
·
05 Mar

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

GlobeNewswire
·
05 Mar